A first-in-class, once-daily oral STAT6 degrader is being studies for eosinophilic asthma.
KT-621 targets STAT6, the key transcription factor driving IL-4/IL-13-mediated Type 2 inflammation, aiming to deliver biologics-like efficacy in an oral form.
The primary endpoint is change from baseline in FEV1.
This trial runs alongside the ongoing BROADEN2 Phase 2b study in moderate to severe atopic dermatitis, with data anticipated mid-2027. Positive results from both could inform dose selection for Phase 3 programs across multiple Type 2 inflammatory diseases (asthma, AD, COPD).
Jared Gollob, MD, Chief Medical Officer, stated:
“Dosing the first patient in our BREADTH study marks an important step in advancing KT-621 as a novel oral treatment option for patients living with chronic, debilitating Type 2 diseases.”
Allergic (atopic) march (click here to enlarge the image). Allergic (Atopic) March refers to the natural history or typical progression of allergic diseases that often begin early in life. These include atopic dermatitis (eczema), food allergy, allergic rhinitis (hay fever) and asthma.
References: